BIOMARKERS FOR PROGNOSIS PREDICTION OF OVARIAN CANCER AND USES THEREOF

The present invention relates to a biomarker for predicting a prognosis of ovarian cancer, and a use thereof. A composition for predicting a prognosis of ovarian cancer using the biomarker comprises an agent which measures the expression level of a protein or mRNA of hypoxia-inducible factor-1 beta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LIM WHA SUN, LEE EUN JI, SONG GWON HWA, KIM HEE SEUNG, PARK SOO JIN
Format:	Patent
Sprache:	eng ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a biomarker for predicting a prognosis of ovarian cancer, and a use thereof. A composition for predicting a prognosis of ovarian cancer using the biomarker comprises an agent which measures the expression level of a protein or mRNA of hypoxia-inducible factor-1 beta (HIF-1ß) and von Hippel-Lindau (VHL). According to the present invention, after primary treatment in patients with high-grade serous cystadenocarcinoma, which is the most common histologic type of ovarian cancer, especially epithelial ovarian cancer, the expression of specific biomarkers is analyzed, and information enabling prediction of a prognosis is provided. Thus, ovarian cancer patients are enabled to receive appropriate prognostic measures. 본 발명은 난소암의 예후 예측용 바이오마커 및 이의 용도에 관한 것으로서, 상기 바이오마커를 이용한 난소암의 예후 예측용 조성물은 HIF-1ß(Hypoxia-inducible factor-1 beta) 및 VHL(von Hippel-Lindau)의 mRNA 또는 단백질의 발현 수준을 측정하는 제제를 포함한다. 본 발명은 난소암, 특히 상피성 난소암(epithelial ovarian cancer)의 가장 흔한 조직학적 유형인 고등급 장액성(high-grade serous cystadenocarcinoma) 난소암 환자들을 대상으로 일차 치료 후 조직을 대상으로 특정 바이오마커의 발현을 분석하여 예후를 예측할 수 있는 정보를 제공함으로써, 난소암 환자가 적절한 예후 조치를 받는 것을 가능하게 할 수 있다.